Navigation Links
Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
Date:1/30/2013

WORCESTER, Mass. and TORONTO, Jan. 30, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today provided an overview on the early breast cancer competitive status of the lead cancer immunotherapy product, AE37, under development at its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).  A detailed update on development plans will be provided during the previously announced conference call scheduled for Thursday, January 31, 2013.  Antigen Express is in late Phase IIb clinical development for early stage breast cancer that has provided very encouraging interim results and Phase I testing in prostate cancer has been completed.

The specific advantage of the cancer immunotherapy product AE37 is in early breast cancer by potentially stimulating the immune system to target HER2 (the target for Herceptin's effect) on breast cancer cells at low levels independent of immune type of the person. This follows in the footsteps of one of the most successful therapeutics ever developed for breast cancer (Herceptin), though AE37 potentially addresses an early breast cancer patient population of unmet need several times more common than those treated with Herceptin. In particular, while Herceptin is approved for use in roughly 25% of early stage breast cancer patients with high expression of HER2, it is not approved for the larger group of women (50% of women with early breast cancer) who have lower levels of expression of the target for Herceptin (HER2). Rather than attacking HER2 cancer cells directly as does Herceptin, AE37 works by stimulating the immune system to recognize HER2. The greater sensitivity of the immune system can thereby be brought to bear to recognize and kill cancer cells in this larger low HER2 expressing early breast cancer population. An additional pot
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
10. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
11. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... PLYMOUTH MEETING, Pa. , Sept. 18, ... eClinical trial solutions, was recognized as the ... 2014 for its ePharmaONE cloud-based eClinical platform. ... portal and electronic trial master file (eTMF), ... informed-consent solution, and ePharmaSolutions, ReferralPlus+ patient screening ...
(Date:9/18/2014)... , Sept. 18, 2014   3D Systems   ... the Simbionix RobotiX Mentor™ , a new robotic surgery ... the first time at the ERUS exhibition in ... (booth #7). Robotic-assisted minimally invasive surgery represents a ... means the needs for training for robotic surgery has increased, ...
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 ... appointments of Dr. Ashraf Hanna , M.D., Ph.D., ... its Board of Directors. Dr. Hanna is the Vice ... and Chief Financial Officer for the Genentech Foundation, while ... Global Head of Business Development and Licensing for Roche ...
Breaking Medicine Technology:ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 33D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3
... , CLEVELAND , Feb. ... and services company focused on global eClinical solutions for the ... Annual DIA Workshop in Japan for Clinical Data ... Coates , Vice President of Sales, will participate in the ...
... Feb. 2 PDI, Inc. (Nasdaq: PDII ), a leading ... announced that Chief Executive Officer Nancy Lurker will present at ... February 8-10, 2010 . , The presentation is scheduled for ... take place at The Grand Hyatt New York. , The webcast of ...
Cached Medicine Technology:DATATRAK Attends 13th Annual DIA Workshop in Japan for Clinical Data Management 2DATATRAK Attends 13th Annual DIA Workshop in Japan for Clinical Data Management 3
(Date:9/18/2014)... Alan Mozes HealthDay Reporter ... it comes to emergency room waiting times, patients seeking care ... staring down the clock than those seen at smaller or ... crowding and our ability to provide timely emergency care varies ... the authors of the new research, Dr. Renee Hsia, an ...
(Date:9/18/2014)... News) -- Daily supplements of selenium or vitamin E ... age-related cataracts among men, a new study indicates. ... could help prevent cataracts. To investigate this further, William ... School in Boston, and his colleagues examined data from ... The trial was initially designed to study prevention of ...
(Date:9/18/2014)... Physicians (CHEST) together with the Chinese Thoracic Society ... CTS that CHEST World Congress 2016 will be ... care, and sleep medicine from around the world ... for spring 2016. , CHEST World Congress ... simulation training, keynote addresses, presentations by leading health-care ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading strategic ... co-founder John Cassimatis was named as one of ... recognizing the region’s top healthcare and life science ... the year. , The Innovation Awards celebrate companies ... to shape the medical industry in Greater Philadelphia ...
(Date:9/18/2014)... 18, 2014 Qualis Health, one of ... a white paper, “Advancing Primary Care through the ... Technology.” , Authors Jeff Hummel, MD, MPH and ... to organizations engaged in the work of becoming a ... can bolster PCMH objectives, such as generating and providing ...
Breaking Medicine News(10 mins):Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2
... , , LEAGUE CITY, Texas, ... has been dedicated to the insurance needs of seniors, with an ... insurance Agent. This has never been more evident than in the ... 3, 2009. , , With the advent of ...
... , , , , ... ), a leading provider of kidney care services for those diagnosed ... ranked 39th on the Environmental Protection Agency,s (EPA,s) FORTUNE 500 List ... as the only dialysis provider among the five healthcare companies featured ...
... , , , ATLANTA, Aug. 3 ... waffles with ketchup, kids are willing to eat anything when they get ... among parents, who want to ensure their kids bridge the gap between ... According to a national survey commissioned by frozen snack maker ...
... ... intensive designed specifically to help hospitals and health systems incorporate social media into marketing ... for Sept 16-17, 2009 in Chicago, IL. , ... Norfolk, Virginia (Vocus) - The Strategy Group announces a ...
... DALLAS Aug. 3, 2009 The new anti-wrinkle facial ... Botox, noticeably reduced frown lines between the eyes, according to ... at UT Southwestern Medical Center. "Our study confirmed that ... wrinkles," said Dr. Rod Rohrich, chairman of plastic surgery at ...
... , PT. RICHMOND, Calif., Aug. 2 Transcept Pharmaceuticals, Inc. ... its exclusive license and collaboration agreement with Purdue Pharmaceutical Products L.P. ... United States. The FDA has established October 30, 2009 as the ... ((R)) New Drug Application (NDA). , , ...
Cached Medicine News:Health News:SLAICO Takes the Medicare Supplement Application Online - Eliminating All Paperwork Offline. 2Health News:DaVita Only Dialysis Provider Named on EPA's FORTUNE 500 List of Green Power Purchasers 2Health News:DaVita Only Dialysis Provider Named on EPA's FORTUNE 500 List of Green Power Purchasers 3Health News:Parents Concerned About Kids' After-School Snacking Habits 2Health News:Innovator's Studio offers Social Media Strategy Intensive Sept 16-17, 2009 2Health News:Innovator's Studio offers Social Media Strategy Intensive Sept 16-17, 2009 3Health News:Dysport proves safe, effective anti-wrinkle treatment, UT Southwestern plastic surgeons find 2Health News:Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States 2
Fluoroperm 151 lens meets special needs of certain patients who need exceptional oxygen permeability for specific corneal condition or lifestyle requirements....
... Thinsite is designed using sophisticated lathing ... concepts. Thinsite lenses feature a center thickness ... ranges. While all plus powered Thinsite lenses ... over standard designs. The unique design eliminates ...
An easy-to-fit RGP daily wear lens with a unique bi-aspheric back surface design that provides excellent patient comfort and adaptation. Boston Envision contact lenses are an ideal alternative for vi...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
Medicine Products: